17,261 trials
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0.0; 50.0; 0.0; 0.0 percentage of participants
SARS-CoV-2 Infection · Acute Kidney Injury
Primary: Change in Whole Blood NAD+ Level — -0.02; 0.06 μg/mL
Small Cell Lung Cancer
Primary: Progression Free Survival — 11 months
Parkinson's Disease · Dysphagia · Dystussia
Primary: Change in Voluntary Cough Peak Flow — 0.17; 0.51 l/s
Facioscapulohumeral Muscular Dystrophy · Limb Girdle Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 7; 0 Participants
Kidney Transplant · Type 1 Diabetes
Primary: The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets. — 0; 2; 2; 1 Participants
Breast Cancer
Primary: Progression-Free Survival — 5.8 weeks
Multiple Sclerosis (MS)
Primary: Mean Overall Response Score (ORS) at Week 52 — 0.04; -0.17; -0.17 score on a scale
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 82.1; 81.2; 81.6; 82.9 score on a scale — p=0.6003
Dyslipidemia
Primary: Estimated Percentage Change in Fasting Triglyceride(s) (TG) — -41.57; -36.79; -38.94 Percent Change — p=0.3084
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in the Chronic Respiratory - Self Administered Individualized (CRQ-SAI) Dyspnea Domain Score at 12 Weeks — 2.00; -0.20 Score on a scale
Pneumonia, Bacterial · Healthy Volunteers · Pneumococcal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), [Stage 1, Group 1] — 11; 5; 5; 5 Participants
SARS CoV-2
Primary: C-reactive Protein — -3.6; -5.5 mg/dL
Chronic Obstructive Pulmonary Disease · Chronic Bronchitis
Primary: Safety of Ivacaftor - Number of Participants With Adverse Events — 19; 6; 7; 3 Participants
Multiple Sclerosis (MS)
Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale